Lightstone Ventures was founded in 2012 by the General Partners and members of the life science teams of Advanced Technology Ventures (ATV) and Morgenthaler. The firm was formed to invest in life science companies. Lightstone investments include: Ardian, Avidia, Caremedic, Ensure, FoldRx, Forsight Vision2, Hypnion, IPC, Ironwood, IVS, MicroVention, Morphotek, Orexigen, Perclose, Plexxikon, Proteolix, Solta, Threshold, and TranS1. Lightstone Ventures have offices in Palo Alto, Calif., Boulder, Colo., Boston, Mass and Dublin, Ireland.
Lightstone Ventures has raised a total of $472 million across 3 funds, their latest being Fund II. This fund was announced on September 20, 2017 and raised a total of $250 million. Lightstone Singapore raised $50 million in 2016 and Lightstone Ventures raised $172 million in 2014. Investments include EarLens, Claret Medical and Disarm Therapeutics and exits include Flex Pharma, Nimbus Apollo and Catabasis Pharmaceuticals.
ALX Oncology is a Burlingame, California-based biotechnology company working on pre-clinical stage immuno-oncology therapies.
Earlens Corporation is a Menlo Park, California-based company.
Cyteir Therapeutics is a Cambridge, Massachusetts-based company.
Associated investment funds
Hanson S. Gifford III
Isabella Zhang, Ph.D., M.B.A.
Kennth D. Noonan
CEO Lightstone Singapore
Mark E Deem
Stacy Enxing Seng
Wen Qi Ho
Documentaries, videos and podcasts
ForSight VISION 2
ForSight VISION 4